Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07096674 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 16, 2026 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial sites expanded: 14 → 24 locationsv4
  2. Study sites: 1 to 14v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 31, 2025 to Aug 12, 2025
    • Site details revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).
Trial Details
NCT Number NCT07096674
Lead Sponsor Centessa Pharmaceuticals (UK) Limited
Conditions
(from sponsor)		 Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Related terms Disorders of Excessive Somnolence, Idiopathic Hypersomnia, Narcolepsy
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov